BioMed Partners invests in Tolremo therapeutics
BioMed Partners has invested in Tolremo therapeutics as part of USD9.3 million Series A financing round. Tolremo therapeutics was founded in March 2017 as a Spin-off from ETH Zürich. Tolremo’s proprietary platform has the potential to change cancer therapy by targeting resistance-causing molecular mechanisms up-front, thereby addressing drug resistance proactively